FindTrial
Sign In

Alternate-Day Buprenorphine Administration. Phase VII - 8

Alternate-Day Buprenorphine Administration. Phase VII

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000226
Enrollment
0
Registered
1999-09-21
Start date
1994-11-30
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders

Brief summary

The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.

Interventions

DRUGBuprenorphine

Sponsors

University of Vermont
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
21 Years to 48 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Drug use—
Opioid withdrawal—
Opioid agonist effects—
Pupil diameter—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026